Vista simple de metadatos

dc.contributorUniv Mayor, Ctr Exercise Physiol Res CIFE, Chilees
dc.contributor.authorPetermann-Rocha, Fanny
dc.contributor.authorHo, Frederick K.
dc.contributor.authorWelsh, Paul
dc.contributor.authorMackay, Daniel
dc.contributor.authorBrown, Rosemary
dc.contributor.authorGill, Jason M. R.
dc.contributor.authorSattar, Naveed
dc.contributor.authorGray, Stuart R.
dc.contributor.authorPell, Jill P.
dc.contributor.authorCelis-Morales, Carlos A. [Univ Mayor, Ctr Exercise Physiol Res CIFE, Chile]
dc.date.accessioned2022-02-28T21:05:09Z
dc.date.available2022-02-28T21:05:09Z
dc.date.issued2020-08
dc.identifier.citationPetermann-Rocha, F., Ho, F. K., Welsh, P., Mackay, D., Brown, R., Gill, J. M., ... & Celis-Morales, C. A. (2020). Physical capability markers used to define sarcopenia and their association with cardiovascular and respiratory outcomes and all-cause mortality: A prospective study from UK Biobank. Maturitas, 138, 69-75.es
dc.identifier.issn0378-5122
dc.identifier.issneISSN: 1873-4111
dc.identifier.otherWOS: 000546894000010
dc.identifier.otherPMID: 32471663
dc.identifier.urihttp://repositorio.umayor.cl/xmlui/handle/sibum/8366
dc.identifier.urihttps://doi.org/10.1016/j.maturitas.2020.04.017
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/32471663/
dc.identifier.urihttps://www.maturitas.org/article/S0378-5122(20)30247-4/pdf
dc.identifier.urihttp://eprints.gla.ac.uk/218027/7/218027.pdf
dc.description.abstractIntroduction: It is unclear what combinations of physical capability markers used to define sarcopenia have the strongest associations with health outcomes. Aim: To compare the associations between different combinations of physical capability markers of sarcopenia with cardiovascular and respiratory outcomes and all-cause mortality. Study design: 469,830 UK Biobank participants were included in this prospective study. Four groups were derived based on combinations of three physical capability markers used to define sarcopenia or severe sarcopenia: gait speed, grip strength and muscle mass. Outcomes studied were all-cause mortality, as well as incidence and mortality from cardiovascular disease (CVD), respiratory disease and chronic obstructive pulmonary disease (COPD). Results: All combinations of physical capability markers used to define sarcopenia or severe sarcopenia identified individuals at increased risk of respiratory disease and all-cause mortality. However, the definition most strongly associated with a wide range of adverse health outcomes was the combination of slow gait speed plus low muscle mass, followed by severe sarcopenia, and the combination of slow gait speed plus low grip strength. The current definition of sarcopenia (low grip strength plus low muscle mass) had the weakest associations with all-cause (HR: 1.35 [95% CI: 1.07 to 1.71]) and respiratory mortality (HR: 1.88 [95% CI: 1.15 to 3.10]), as well as respiratory disease (HR: 1.38 [95% CI: 1.11 to 1.73]) and COPD incidence (HR: 2.08 [95% CI: 1.14 to 3.79]). Conclusions: Associations of sarcopenia with adverse outcomes were strongest when sarcopenia was defined as slow gait speed plus low muscle mass, followed by severe sarcopenia, suggesting that this combination of physical capability markers should be still considered in the diagnosis of sarcopenia.es
dc.description.sponsorshipUK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. All authors had final responsibility for submission for publication. FP-R receives financial support from the Chilean Government for doing her PhD (ANID-Becas Chile).es
dc.format.extent22 p., PDFes
dc.language.isoen_USes
dc.publisherElsevier Ireland Ltdes
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chilees
dc.titlePhysical capability markers used to define sarcopenia and their association with cardiovascular and respiratory outcomes and all-cause mortality: A prospective study from UK Biobankes
dc.typeArtículo o Paperes
umayor.indizadorCOTes
umayor.politicas.sherpa/romeoLicencia CC BY-NC-ND 4.0. Disponible en: https://v2.sherpa.ac.uk/id/publication/17095es
umayor.indexadoWeb of Sciencees
umayor.indexadoPUBMEDes
dc.identifier.doi10.1016/j.maturitas.2020.04.017
umayor.indicadores.wos-(cuartil)Q2
umayor.indicadores.scopus-(scimago-sjr)SCIMAGO/ INDICE H: 105 H
umayor.indicadores.scopus-(scimago-sjr)SJR 1.35


Vista simple de metadatos



Modificado por: Sistema de Bibliotecas Universidad Mayor - SIBUM
DSpace software copyright © 2002-2018  DuraSpace